AstraZeneca stock trades lower as fresh approvals fail to offset technical pressure

Traders Union
All News
Financial News
AstraZeneca slips 0.62% to GBX 13,528

Highlights

AstraZeneca and Daiichi Sankyo received FDA approval for Enhertu plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer in the US, based on phase 3 superiority over standard care.
The EU approved subcutaneous self-administration of Saphnelo for adults with systemic lupus erythematosus, expanding AstraZeneca's international treatment options.
These regulatory wins bolster AstraZeneca's therapeutic presence and growth prospects in both the United States and major European markets.

FDA and EU drug approvals expand global market reach

AstraZeneca, together with Daiichi Sankyo, secured FDA approval in the United States for Enhertu in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer, based on phase 3 results demonstrating clear benefits over standard care. In Europe, the company received EU approval for subcutaneous self-administration of Saphnelo for adults with systemic lupus erythematosus. Both decisions enhance AstraZeneca's therapeutic footprint in major international markets.

Mixed momentum signals amid support at Ichimoku Kijun

From a technical perspective, the nearest dynamic support is defined by the Ichimoku Kijun at GBX 13,523.00, with MA-20 and MA-50 acting as short-term resistance and support levels respectively. Momentum signals are mixed: the daily MACD and ADX indicate ongoing bullish momentum, while oscillators such as the RSI (55.49, mildly bullish), Stoch RSI (oversold), and CCI (negative) show some caution, and Bull/Bear Power flags overbought conditions with persistent buyer dominance intraday. The Awesome Oscillator remains neutral, not providing a clear directional signal. The move toward the lower end of today’s range (GBX 13,466–13,834) highlights a short-term divergence, where selling pressure has emerged even as long-term momentum stays positive.

Upside favored as long-term momentum tempers downside risk

Over the next five trading days, AZN is likely to trade within a volatility band between GBX 13,400 and GBX 13,900. The probability of upward movement is high, with trend alignment and long-term momentum remaining supportive, making a sustained decline less likely. Baseline expectation is for consolidation between GBX 13,523–13,400 as support and GBX 13,834–13,900 as resistance. A bullish break above GBX 13,900 would open potential for new weekly highs, while a persistent drop below GBX 13,400 could prompt short-term declines, though broader trends should contain downside risk.

Viktoras Karapetjanc, analyst at Traders Union, sees AstraZeneca as maintaining strong medium- and long-term momentum despite the brief pullback. He believes recent FDA and EU approvals further reinforce the company's dominant international position, boosting market sentiment. The analyst notes technicals remain constructive, with clear support above GBX 13,400 and a robust resistance range ahead. Karapetjanc remains optimistic about the stock’s prospects for upward continuation. "With solid fundamentals and improving sentiment, I expect AstraZeneca to lean bullish and potentially test new highs if it breaks above GBX 13,900 in the near term."

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.